Modern Chinese medicine industry flourishes

[Hui Cong Pharmaceutical Industry Network] In recent years, Chinese medicine policy has been continuously improved and gradually upgraded to the national level. The "National Innovation Driven Development Strategy Outline", "Health China 2030" Planning Outline and "Chinese Medicine Development Strategy Planning Outline (2016-2030)" and other documents all listed TCM science and technology innovation as a development focus, strengthening Chinese medicine Scientific and technological innovations put forward clear requirements.

The "13th Five-Year Plan for the Innovation of Traditional Chinese Medicine Science and Technology" issued recently, proposed to accelerate the promotion and innovation of Chinese medicine, realize the revitalization of Chinese medicine, and propose "improving the international standards for Chinese medicine, forming no less than 50 items." Pharmacopoeia standards and 100 industry standards, achieving drug registration of 20 to 30 Chinese patent medicine varieties and drug registration of 5 to 10 Chinese patent medicine varieties in Europe and the United States; strengthening international cooperation in Chinese medicine research and other strategic objectives, for Chinese medicine products international It is a great opportunity to create time, place and people.

The total industrial output value has increased significantly

Guided by scientific and technological innovation, the modern Chinese medicine industry is booming. The total output value of the Chinese medicine industry has increased from 23.4 billion yuan in 1996 to 786.7 billion yuan in 2015, accounting for a proportion of the total output value of the pharmaceutical industry from 1/5 to 1/3. Pharmaceutical products and services are accelerating to the world.

According to WHO statistics, Chinese medicine has been recognized in government legislation in 29 countries and regions including Australia, Canada, Austria, Singapore, and Vietnam. 18 countries and regions have included Chinese medicine in medical insurance; Chinese medicine has been in Russia, Singapore, and Cuba. Registered in Vietnam, Vietnam and other countries, a group of Chinese medicine companies represented by Shenwei, Lanzhou Foci, and Di'ao Group actively apply for international high-end certification. At present, there are 4 kinds of traditional Chinese medicines in China that have been approved by the FDA for clinical research. A number of Chinese herbal medicines have been included in the US Pharmacopoeia and the European Pharmacopoeia.

Pharmaceutical enterprises network worldwide

In line with the trend of Chinese medicine internationalization, China's traditional Chinese medicine products have mushroomed and developed rapidly. In March 2012, Diao Group's “Dio Xinxuekang Capsule” was approved by the Dutch Pharmaceutical Examination Bureau for registration and approval; in 2016, Tasly Modern Chinese Medicine Danshen Capsule obtained EU plant drug registration approval and successfully entered the European market as a drug.

At the same time, some internationalized Chinese medicine companies began to establish a global marketing network through investment and mergers and acquisitions. In 2013, Tasly invested 1.82 million euros to acquire Dutch Shenzhou Pharmaceutical Center Co., Ltd., a subsidiary of Holland Haidebao Management Co., Ltd., and established the Dutch Shenzhou Tianshili Pharmaceutical Group Co., Ltd.; in September 2016, Lingling Pharmaceuticals Co., Ltd. Strategic cooperation with Israel HealthWatch, invested 15 million US dollars to become its largest shareholder.

Conclusion <<<

Traditional Chinese medicine has gradually become in line with the world. However, the road to internationalization of Chinese medicine is long and arduous. On the one hand, national laws, regulations and cultural differences have become one of the main obstacles to the overseas development of Chinese medicine. For example, the US FDA generally does not recognize natural botanicals including traditional Chinese medicines. Therefore, although some herbs are used in the United States, most of the herbs are still sold as dietary supplements. On the other hand, high-level Chinese medicine internationalization professionals Lack of demand, the unbalanced development of Chinese medicine education has also affected the international development of Chinese medicine to a certain extent.

The internationalization of Chinese medicine cannot be simply defined as the exchange and cooperation of certain specific Chinese medicine products trade and health services in a certain country or region overseas, but under the guidance of the state and industry authorities. We will continue to promote the development of traditional Chinese medicine, health care, and industry overseas, so that the international community can recognize and apply Chinese medicine, and promote the establishment of a Chinese medicine health service system. At the same time, the Chinese medicine education is included in the national education legal system of the country, providing a carrier for the overseas survival of the Chinese civilization. Therefore, in addition to the successful experience of companies that have been involved in the international arena, we must closely cooperate with the national “One Belt, One Road” development strategy, build a platform for international exchange of Chinese medicine, cultivate a team of Chinese medicine international talents, and cultivate Chinese medicine in the world. The right to speak in the health and wellness system.

Editor in charge: Zhao Yang